Abstract: The disclosure relates to doubly attenuated malaria parasites that have had the functionality of LISP2 and PlasMei2 genes interrupted through genetic manipulation. The double attenuated malaria parasites disclosed herein are useful for methods and compositions for stimulating of vertebrate host immune systems because of the complete cessation of lifecycle progression in the late liver stage, while providing a comprehensive antigenic presentation representing wildtype liver stage parasites. The disclosure also relates to the additional blood stage and gametocyte antigens to compositions of genetically attenuated malaria parasites (GAPs) to enhance efficient immune stimulation and prevention of disease and transmission related to the presence of blood stage parasites.

Abstract: Disclosed are an attenuation system and the use thereof for attenuating plasmodia, specifically the use of an EF1g gene for attenuating plasmodia. The attenuation system regulates the expression or degradation of the EF1g gene by using a regulatory system, thereby controlling the growth of plasmodia and achieving the attenuation of plasmodia.

Abstract: The present invention is directed to novel polynucleotides, polypeptides, and polyproteins of Mycoplasma surface proteins, all of which are useful in detecting infection and for the preparation of vaccines for treating and preventing diseases in swine and other animals. Vaccines provided according to the practice of the invention are effective against Mycoplasma infections. Detection and therapeutic polyclonal and monoclonal antibodies are also a feature of the present invention. Assays, kits, systems, and nanoparticle encapsulated compositions related to the polynucleotides, polypeptides, polyproteins, antibodies or fragments, derivatives, and variants thereof are also disclosed.

Abstract: Animal protein-free, solid-form Clostridial toxin pharmaceutical compositions comprising a Clostridial toxin active ingredient and at least two excipients.

Abstract: [Problem] Provided is a food composition containing acetic bacterial cells which has a good aroma, and a method of producing the food composition. [Solution] The food composition containing acetic bacterial cells of the present invention contains acetic acid and n-butyric acid, the peak area ratio between which is 40:1 to 1:20, as measured by solid phase micro extraction gas chromatography-mass spectrometry for odor components in the food composition. Surprisingly, such a food composition has a fermentative aroma like rice bran which can stimulate consumers' appetite.

Abstract: Methods of producing a pathogen with reduced replicative fitness are disclosed, as are attenuated pathogens produced using the methods. In particular examples, the method includes deoptimizing one or more codons in a coding sequence, thereby reducing the replicative fitness of the pathogen. Methods of using the attenuated pathogens as immunogenic compositions are also disclosed.

Abstract: A vaccine vector comprising a first polynucleotide encoding the antigenic polypeptide selected from the group consisting of SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 8, SEQ ID NO: 9, or any combination thereof.

Abstract: The present invention relates to the field of medicine and in particular to Parkinson's disease (PD). Specifically the present invention relates to methods and means for early detection of PD. The invention relates also to methods and means for treatment or prophylaxis of PD. In the method of the invention a probability of a subject developing or having Parkinson's disease (PD) is determined by measuring the relative abundances of one or multiple microbial taxa in a sample from a subject; and the probability of the subject developing or having PD is determined based on the measured abundances. The present invention provides a novel approach for the diagnostics of PD.

Abstract: The present invention relates to: human-derived Lactobacillus fermentum MG4231 or Lactobacillus fermentum MG4244; and a pharmaceutical composition, a food composition, a quasi-drug composition and a health functional food for preventing or treating obesity-related diseases, all of which include the same as an active ingredient. A Lactobacillus fermentum MG4231 strain or MG4244 strain of the present invention exhibits an anti-obesity activity for inhibiting a lipase enzyme activity, inhibiting preadipocyte differentiation and inhibiting triglyceride accumulation, has an excellent ability to form colonies on the epithelial cells of a digestive tract by means of an excellent auto-aggregation ability, and has resistance to acid and bile, thereby being variously usable as a pharmaceutical composition, a food composition, a quasi-drug composition and a health functional food for the purpose of treating and preventing obesity-related diseases.

Abstract: Provided are therapeutic compositions containing Ecobiotic™ populations for prevention, treatment and reduction of symptoms associated with a dysbiosis of a mammalian subject such as a human.

Abstract: Provided are therapeutic compositions containing Ecobiotic™ populations for prevention, treatment and reduction of symptoms associated with a dysbiosis of a mammalian subject such as a human.

Abstract: The present disclosure relates to a composition comprising a Lactobacillus plantarum CJLP475 strain deposited under Accession No. KCCM12287P; and a Lactobacillus plantarum CJLP243 strain deposited under Accession No. KCCM11045P, and use thereof.

Abstract: Provided are therapeutic compositions containing Ecobiotic™ populations for prevention, treatment and reduction of symptoms associated with a dysbiosis of a mammalian subject such as a human.

Abstract: The present invention relates to the composition and method of preparing an immunogen designated as I-spga consisting of a complex antigen prepared from 18 to 26 species of pathogenic microorganisms isolated from patients, inactivated with binary ethyleneamine (BEI) and formalin, diluted in a SPGA immunopotentiator mixed with QS-21 adjuvant. By inoculating the hens with the I-spga immunogen, hyperimmune eggs (Immunospga) are obtained which contain immunologically active proteins specific to the 18-26 antigens used for immunization. The immune response of the hens is specific to the used antigens by amplification of the antigenic signal by the SPGA immunopotentiator and due to a special immunization program that allows the immune system to act complex and intense: The I-spga complex antigen contains 18-26 microorganisms isolated from patients, bacterial bodies, components from bodies obtained by ultrasonography, cilia, exotoxins, endotoxins, spores, viruses, fungi or yeasts.

Abstract: A hybridoma cell stain and a monoclonal antibody secreted therefrom and application thereof belong to the technical field of prevention and treatment of Trichinella spiralis (T. spiralis). Aiming at the technical problem of how to specifically diagnose trichinellosis, the disclosure provides a hybridoma cell strain deposited under an accession number of CGMCC No. 18317. Tests show that the monoclonal antibody Ts-ZH68-2A4-Ab secreted by the hybridoma cell strain can compete with the positive serum of pigs infected with T. spiralis for binding to Ts-ZH68 antigen, and the recognition peptide is 222GVDRSATCQGDSGGP236. The monoclonal antibody of the disclosure and the Ts-ZH68 protein B cell epitope polypeptide recognized by the monoclonal antibody can be used to prepare a reagent or a vaccine for diagnosing or preventing infection of T. spiralis, laying the foundation for establishment of a serological diagnosis method of T. spiralis.

Abstract: This disclosure is directed to immune treatment of a disease (e.g., an infectious disease) using a fusion protein in combination with an anti-chemorepellant agent. In particular, the fusion protein comprises an antigen-binding domain (e.g., an antibody or antibody fragment) and a stress protein domain.

Abstract: Animal protein-free, solid-form Clostridial toxin pharmaceutical compositions comprising a Clostridial toxin active ingredient and at least two excipients.

Abstract: The present invention provides methods and compositions to reduce binding of fibrinogen to the ClfA in a gram positive bacterial infections using monoclonal antibody, a polyclonal antibody, an antigen-binding antibody fragment or a composition that specifically binds to a portion of ClfA with the sequence of SEQ ID No: 15, SEQ ID NO: 16, SEQ ID NO: 17, and SEQ ID NO: 18.

Abstract: The present invention provides isolated polypeptides isolatable from a Fusobacterium spp. Also provided by the present invention are compositions that include one or more of the polypeptides, and methods for making and methods for using the polypeptides.

Abstract: Described are non-toxigenic Clostridium difficile strains and spores. Also described are vaccines comprising the Clostridium difficile spores. Further described are methods of preventing or treating a Clostridium difficile infection in a subject in need thereof.